Physician profile
Mohammad Madjid
NPI 1083868145
$110,339.43
in general payments reported to CMS, 2019-2025
20 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $35K · 2021: $3,290 · 2022: $30K · 2023: $8,728 · 2024: $6,225 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,828 · Food and Beverage: $5,677 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,909 · Travel and Lodging: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,827.75 |
| Food and Beverage | $5,676.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,909.00 |
| Travel and Lodging | $1,284.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $92,664.86 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $6,529.43 | 2022-2025 | Leqvio |
| Abbott Laboratories | $3,144.00 | 2022-2025 | Pressurewire, Dragonfly Opstar, Coroflow |
| Sanofi-Aventis U.S. LLC | $2,691.80 | 2019 | |
| Seqirus USA INC | $2,500.00 | 2021-2022 | |
| Abiomed | $670.44 | 2023-2025 | Impella |
| Shockwave Medical, INC | $526.94 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $329.22 | 2022-2023 | Farxiga |
| Heartflow, INC. | $282.54 | 2025 | |
| Penumbra, INC. | $234.54 | 2022 | |
| Boston Scientific Corporation | $165.55 | 2025 | Emerge Push |
| Regeneron Pharmaceuticals, INC. | $137.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.03 | 2024 | Xarelto |
| Amgen INC. | $122.63 | 2024-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $100.32 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $43.02 | 2022 | |
| Lantheus Medical Imaging, INC. | $27.56 | 2024 | |
| Chiesi USA, INC. | $18.55 | 2022 | |
| Medtronic, INC. | $14.55 | 2022 | |
| Merck Sharp & Dohme LLC | $13.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Madjid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.